Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCALA trial of galvokimig in moderate-to-severe COPD with chronic bronchitis
jRCT2041260143Phase 2Not yet recruiting
- Sponsor
- UCB
- Start
- Nov 2026
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB) comparing Galvokimig with Placebo (2 arms). Primary endpoint: Time to first moderate or severe acute exacerbation of chronic obstructive pulmonary disease. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
galvokimig
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)
Beyond the preview
Go deeper on jRCT2041260143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041260143.